Analysts defend Abbott Labs' stock after Thursday's 'too punitive' sell-off
-
最新报道：Abbott Laboratories' stock rebounded Friday after analysts defended the company following a sharp sell-off triggered by weaker-than-expected Q2 earnings. Shares dropped 6% Thursday but regained 3% as JPMorgan and Wells Fargo reiterated "overweight" ratings, citing strong fundamentals in Abbott's medical device and nutrition segments. CEO Robert Ford acknowledged "short-term headwinds" but emphasized long-term growth drivers, including new product launches in diabetes care. The sell-off was deemed "overdone" by analysts, who noted Abbott's diversified portfolio and $8.5 billion in cash reserves position it well for recovery. Full-year revenue guidance was maintained at $42-$44 billion despite currency impacts.
下一篇
FBI agents were told to 'flag' any Epstein records that mentioned Trump, Sen. Durbin says
- Former President Donald Trump is facing renewed scrutiny after FBI documents revealed undi...
24小时热点
热点专题
418271